Immunome is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop antibody therapeutics designed to change the way diseases are being treated. Co.'s primary focus areas are oncology and infectious disease. Co. is advancing two programs: a three-antibody cocktail (IMM-BCP-01) for potential treatment and prophylaxis of SARS-CoV-2, and an antibody (IMM-ONC-01) against interleukin 38, an immune checkpoint, for the potential treatment of various solid tumors. The IMNM average annual return since 2020 is shown above.
The Average Annual Return on the IMNM average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether IMNM average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the IMNM average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|